ROS1 Targeted Therapies: Current Status

被引:32
作者
Azelby, Christine M. [1 ]
Sakamoto, Mandy R. [1 ]
Bowles, Daniel W. [2 ,3 ]
机构
[1] Univ Colorado, Dept Med, Anschutz Med Campus, Aurora, CO USA
[2] Univ Colorado, Div Med Oncol, Dept Med, Anschutz Med Campus,12801 E 17th Av, Aurora, CO 80045 USA
[3] Rocky Mt Reg VA Med Ctr, Aurora, CO 80045 USA
关键词
ROS1; Non-small cell lung cancer; Targeted therapy; Molecular drivers; CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; ALK INHIBITOR; PAN-TRK; CRIZOTINIB; FUSION; ENTRECTINIB; CABOZANTINIB; REARRANGEMENT; MUTATION;
D O I
10.1007/s11912-021-01078-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of Review Molecular drivers are increasingly identified as therapeutic targets for non-small cell lung cancer (NSCLC). This review focuses on the role of ROS1 inhibitors in treating relapsed/metastatic ROS-1 altered (ROS1+) NSCLC. Recent Findings Four FDA-approved drugs have significant activity against ROS1+ NSCLC: crizotinib, ciritinib, lorlatinib, and entrectinib. Each drug yields an overall response rates exceeding 60% with ciritinib, lorlatinib, and entrectinib possessing intracranial activity. The drugs have manageable toxicity profiles. ROS1 alterations are rare molecular drivers of NSCLC that can be effectively treated with a variety of ROS1-targetd drugs. New agents are being identified that may treat resistance mutations.
引用
收藏
页数:9
相关论文
共 51 条
[41]   Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors [J].
Sehgal, Kartik ;
Patell, Rushad ;
Rangachari, Deepa ;
Costa, Daniel B. .
TRANSLATIONAL CANCER RESEARCH, 2018, 7 :S779-S786
[42]   Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 [J].
Shaw, A. T. ;
Riely, G. J. ;
Bang, Y-J ;
Kim, D-W ;
Camidge, D. R. ;
Solomon, B. J. ;
Varella-Garcia, M. ;
Iafrate, A. J. ;
Shapiro, G., I ;
Usari, T. ;
Wang, S. C. ;
Wilner, K. D. ;
Clark, J. W. ;
Ou, S-H, I .
ANNALS OF ONCOLOGY, 2019, 30 (07) :1121-1126
[43]   Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer [J].
Shaw, Alice T. ;
Ou, Sai-Hong I. ;
Bang, Yung-Jue ;
Camidge, D. Ross ;
Solomon, Benjamin J. ;
Salgia, Ravi ;
Riely, Gregory J. ;
Varella-Garcia, Marileila ;
Shapiro, Geoffrey I. ;
Costa, Daniel B. ;
Doebele, Robert C. ;
Long Phi Le ;
Zheng, Zongli ;
Tan, Weiwei ;
Stephenson, Patricia ;
Shreeve, S. Martin ;
Tye, Lesley M. ;
Christensen, James G. ;
Wilner, Keith D. ;
Clark, Jeffrey W. ;
Iafrate, A. John .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (21) :1963-1971
[44]  
Shiau CJ, 2017, DIAGNOSTIC MOLECULAR PATHOLOGY: A GUIDE TO APPLIED MOLECULAR TESTING, P287, DOI 10.1016/B978-0-12-800886-7.00023-6
[45]   ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases [J].
Song, Zhengbo ;
Zheng, Yuhui ;
Wang, Xuzhou ;
Su, Haiyan ;
Zhang, Yiping ;
Song, Yong .
JOURNAL OF THORACIC DISEASE, 2017, 9 (10) :3919-+
[46]   Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer [J].
Sun, Thomas Yang ;
Niu, Xiaomin ;
Chakraborty, Amit ;
Neal, Joel W. ;
Wakelee, Heather A. .
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (02) :E21-E24
[47]  
Suryavanshi M, 2017, LUNG INDIA, V34, P411, DOI 10.4103/lungindia.lungindia_116_17
[48]   Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model [J].
Tappenden, Paul ;
Carroll, Christopher ;
Hamilton, Jean ;
Kaltenthaler, Eva ;
Wong, Ruth ;
Wadsley, Jonathan ;
Moss, Laura ;
Balasubramanian, Sabapathy .
HEALTH TECHNOLOGY ASSESSMENT, 2019, 23 (08) :1-+
[49]   Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer [J].
Wu, Yi-Long ;
Yang, James Chih-Hsin ;
Kim, Dong-Wan ;
Lu, Shun ;
Zhou, Jianying ;
Seto, Takashi ;
Yang, Jin-Ji ;
Yamamoto, Noboru ;
Ahn, Myung-Ju ;
Takahashi, Toshiaki ;
Yamanaka, Takeharu ;
Kemner, Allison ;
Roychowdhury, Debasish ;
Paolini, Jolanda ;
Usari, Tiziana ;
Wilner, Keith D. ;
Goto, Koichi .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (14) :1405-+
[50]   Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer [J].
Yoshida, Tatsuya ;
Oya, Yuko ;
Tanaka, Kosuke ;
Shimizu, Junichi ;
Horio, Yoshitsugu ;
Kuroda, Hiroaki ;
Sakao, Yukinori ;
Hida, Toyoaki ;
Yatabe, Yasushi .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (28) :3383-+